Hi all,
Since everyone is sharing their estimated revenue from Coviu & Phenix deals, I thought I would share mine which is quite conservative. Assuming Coviu has around 25,000 telehealth consultations a day and maybe 5,000 for Phenix (just a wild guess). If approx. 50% of those are respiratory related consultations, that's 12,500 consultations for Coviu and 2,500 consultations for Phenix.
As stated in my previous post (#
44897117), I expect that ResAppDx-EU will be sold as an add-on on Coviu, where GPs/clinics will need to pay extra to use the add-ons to their account. I don't think it'll be rolled out as a standard feature on their telehealth platform. Therefore, perhaps an initial take up of say around 10-20% in the first month would be a reasonable estimate, which equates to between 1250 - 2500 uses a day. At $5 (the minimum), that's
an estimate of $6250 - $12,500 a day in the first month,
from Coviu alone, at $5 per test.In terms of Phenix, I'm unsure if this will be rolled out as a standard feature. IMO a GP might not use ResApp-DX for all respiratory related consultations (might not be required). It'll be great if they do that, but until that's been shown the case, I think a 50/50 chance of a GP will use it is an optimistic outcome.
Assuming that Phenix rolls out ResAppDX-EU as a standard feature on their platform meaning all users can access it, and a 50% chance that a GP will use ResAppDX-EU for respiratory related consultation, that equals to approximately 1,250 uses per day. (5,000 x (50% respiratory related consultations) x 50% chance of using the app).
That's equivalent of $6,250 a day from Phenix, again at $5 per test.Combining the two above,
my estimate would be between $12,500-$20,000 a day from both Coviu and Phenix. This is an equivalent of $4.5m-$7.3m yearly revenue.However, this is just an estimate based on the initial 'introductory phase' as I believe it'll take time for GP/clinics to take on the use of ResAppDx-Eu. Obviously there are many assumptions in my calculations above but I believe these are reasonable and not overly optimistic.
These estimates are not jaw-dropping numbers, but I think it's a pretty good damn start for ResApp, as many of long term SHs like me have been waiting for the $$$ to roll in. And remember this is only 2 telehealth companies within Australia
Not long to go now before the end of June!
GLTAH and DYOR
